Glaucoma and the dry eye syndrome

Cover Page


The development of the dry eye syndrome in glaucoma patients is a pressing challenge during last 10 years. As reported by multiple investigators, the main causes for the development of corneal and conjunctival xerosis in such patients are: toxic action of preservatives in hypotensive ophthalmic medications, pharmacological effect of beta-blockers, and corneal trauma at the time of diagnostic manipulations. A meaningful action to prevent this disease is a to switch to either a preservative-free hypotensive ophthalmic medications, or to those containing a non-toxic preservative. A review of the literature was also done to find the causes, prevention and treatment methods of the dry eye syndrome in glaucoma patients

About the authors

Vladimir Vsevolodovich Brjesky

Pediatric State Medical Academy

doctor of medical science, professor, head of department. Department of Ophthalmology

Mukhammed Radukhan

Pediatric State Medical Academy

Department of Ophthalmology


  1. Бржеский В. В., Сомов Е. Е. Роговично-конъюнктивальный ксероз (диагностика, клиника, лечение). Изд. 2-е, част. перераб. и доп. СПб.: Левша. Санкт-Петербург; 2003: 120.
  2. Бржеский В. В., Сомов Е. Е. Синдром «сухого глаза» у больных с врожденной глаукомой. Клиническая офтальмология. 2003; 4 (3): 139-141.
  3. Воронцова О. А. Некоторые особенности клинического течения синдрома «сухого глаза» у детей. Автореф. дис.. канд. мед. наук. СПб.; 2013: 23.
  4. Лебедев О. И., Калижникова Е. А., Яворский А. Е. Механизмы и результаты действия бензалкония хлорида на ткани глаза. Клиническая офтальмология. 2013; 2: 63-65.
  5. Муратова Н. В. Влияние бета-блокаторов на синдром «сухого глаза» и его коррекция. Автореф. дис. канд. мед. наук. М.; 2005: 23.
  6. Ткаченко Н. В. Значение исследования состояния конъюнктивы и роговицы у пациентов с первичной открытоугольной глаукомой. Автореф. дис.. канд. мед. наук. СПб.; 2011: 18.
  7. Baudouin C., Garcher C., Haouat N. et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101: 454-460.
  8. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008; 86 (7): 716-726.
  9. Baudouin C. Dry eye disease and glaucoma. In: Ocular surface disorders. Ed. By: J. M. Benitez-del-Castillo, M. A. Lemp. London etc.; 2013: 89-94.
  10. Bhamra J., Wong J., Gohill J. Oral pilocarpine for the treatment of keratoconjunctivitissiccawithcentralcornealirregularity.J. Cataract Refract. Surg. 2003; 29 (11): 2236-2238.
  11. Bonomi L., Perfetti S., Noya E. et al. Comparisson of effects od nine beta-adrenargic blocking agents on intraocular pressure in rabbits. Graefe's Arch. Exp. Ophthalmol. 1979; 210 (1): 1-8.
  12. Brandt J. D., Wittpenn Y. R., Katz L. J. et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Amer. J. Ophthalmol. 1991; 112: 297-301.
  13. Burgalassi S., Panichi L., Chetoni Р. Et al. Development of а simple dry еуе model in the albino rabbit and evaluation of some tear substitutes. Ophthalmic Res. 1999; 31: 229-235.
  14. Coakes R. L., Mackie I. A., Seal D. V. Effects of long-term treatment with timolol on lacrimal gland function. Brit. J. Ophthalmol. 1981; 65 (9): 603-605.
  15. Cohen G. M. Caspases: the executioners of apoptosis. Biochem J. 1997; 326: 1-16.
  16. Debbasch C., Pisella P.-J., De Saint J. M. et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest. Ophthalmol. Vis Sci. 2001; 42 (11): 2525-2533.
  17. De Saint J. M., Brignol F., Bringuier A. F.etal. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 1999; 40 (3): 619-630.
  18. Epstein S. P., Ahdoot M., Marcus E., Asbell P A. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J. Ocul. Pharmacol. Ther. 2009; 25 (2): 113-119.
  19. Erb C., Gast U., Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefe's Arch. Exp. Ophthalmol. 2008; 246: 1593-1601.
  20. Fechtner R. D., Godfrey D. G., Budenz D. et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010; 29: 618-621.
  21. Fox R. I., Michelson P Approaches to the treatment of Sjogren's syndrome. J. Rheumatol. (Suppl.; Canada). 2000; 61 (12): 15-21.
  22. Gobbels M., Monks T., Spitznas M. Effect of topical 0.5 % timolol on tear flow in patients with primary open-angle glaucoma as assessed by fluorophotometry. Germ. J. Ophthalmol. 1993; 2 (4-5): 241-245.
  23. Herreras J. M., Pastor J. C., Calonge M., Asensio V. M. Ocular surfacealterationafterlong-term treatment withanantiglaucomatous drug. Ophthalmology. 1992; 99 (7): 1082-1088.
  24. Jaenen N., Baudouin C., Pouliquen P et al. Ocular symptoms and sings with preserved and preservative-free glaucoma medications. Europ. J. Ophthalmol. 2007; 17: 341-349.
  25. Jones L. T. The lacrimal secretory system and its treatment. Amer. J. Ophthalmol. 1966; 62 (1): 47-60.
  26. Kuppens E. V., de Jong C. A., Stolwijk T. R., et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Brit. J. Ophthalmol. 1995; 79 (4): 339-342.
  27. Leung E. W., Medeiros F. A., Weinreb R. N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma. 2008; 17: 350355.
  28. Li J., Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. J. Biol. Chem. 1995; 270: 3203-3211.
  29. Mackei I. A., Seal D. V., Pescod J. M. Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for ad-verce reaction. Brit. J. Ophthalmol. 1977; 61 (5): 354.
  30. Mannucci L. L., Fregona I., Di Gennaro А. Use of a new lachrymal substitute (TS Polysaccharide) in Contactology. J. Med. Contactol-ogy and Low Vision. 2000; 1 (1): 6-9.
  31. Nagler R. M., Nagler A. The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch. Oral Biol. 2001; 46 (8): 689-695.
  32. Nakamura T., Teshima M., Kitahara T., et al. Sensitive and real-time method for evaluating corneal barrier considering tear flow. Biol. Pharm. Bull. 2010; 33 (1): 107-110.
  33. Nelson J., Friedlaender M., Yeatts R. et al. Oral pilocarpine for symptomatic relief of ceratoconjunctivitis sicca in patients with Sjogren's syndrome. Lacrimal gland, tear film and dry eye syndromes/Ed.: Sullivan D., Dartt D., Meneray M.). New York: Plenum Press; 1988: 979-983.
  34. Nenciu A, Stefan C, Ardelean C. Structural and immunohistochemi-cal changes of conjunctiva induced by topical glaucoma medication. Oftalmologia. 2004; 48 (1): 35-42.
  35. Norn M. S. Desiccation of the precorneal film. I. Corneal wettingtime. Acta ophthalmol. 1969; 47 (4): 865-880.
  36. Nuzzi R., Finazzo C., Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjuctiva and lachrymal response. Int. Ophthalmol. 1998; 22 (1): 31-35.
  37. Ohtsuki M., Yokoi N., Morti K. et al. Adverse effects of beta-blocker eye-drops on the ocular surface. Nippon Gakkai Zasshi. 2001; 105 (3): 49-54.
  38. Patarca R., Fletcher M. A. Effects of benzalkonium salts on eukaryotic and microbial G-protein-mediated processes and surface membranes. Crit. Rev. Oncog. 1995; 6: 327-356.
  39. Paulsen F., Langer G., Hoffmann W., Beny М. Human lacrimal gland mucins. Cell Tissue Res. 2004; 316: 167-177.
  40. Pisella P. J., Debbasch C., Hamard P. et al. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Brit. J. Ophthalmol. 2002; 86 (4): 418-423.
  41. Pisella P. J., Debbasch C., Hamard P., et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis Sci. 2004; 45 (5): 1360-1368.
  42. Rossi G. C., Tinelli C., Pasinetti G. M. et al. Dry eye syndrome-related quality of life in glaucoma patients. Europ. J. Ophthalmol. 2009; 19: 572-579.
  43. Schirmer O. Studie zur Physiologie und Pathologie der Tranenab-sonderung und Tranenabfuhr. Albrecht v. Graefes Arch. Ophthalmol. 1903. Bd 56, H. 2. S. 197-291.
  44. Shimazaki J., Hanada K., Yagi Y., et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5 % timolol and 0.12 % unopros-tone. Brit. J. Ophthalmol. 2000; 84 (11): 1250-1254.
  45. Strempel I. Intensitat und Dauer der Tranenfilmaufrisszeitanderun-gen durch handelsubliche Betablocker und ihre Kombination mit Tranenfilmersatzmitteln. Ophthalmologica. 1987; 195 (2): 61-68.
  46. Thygesen J., Aaen K., Theodorsen F., et al. Short-term effect of la-tanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2000; 78 (1): 37-44.
  47. Tseng S. C. G. Evaluation of the ocular surface in dry - eye conditions. Intern. Ophthalmol. Clin. 1994; 34 (1): 57-69.
  48. Vivino F. B. The treatment of Sjogren's syndrome patients with pilocarpine-tablets. Scand J. Rheumatol. (Suppl.; Norway). 2001; 115: 1-9.



Abstract - 862

PDF (Russian) - 475



Copyright (c) 2014 Brjesky V.V., Radukhan M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies